Scientists Tested a Toad Venom Psychedelic on Treatment-Resistant Depression. Here's What Happened.
A phase 2b trial funded by AtaiBeckley (Eli Lilly subsidiary) tested a toad venom-derived psychedelic, mebufotenin, as a nasal spray for treatment-resistant depression. The study, published in JAMA, found that an 8 mg dose improved depression scores and was safe, with benefits lasting up to eight weeks. The drug will proceed to phase 3 trials. Critics note the antidepressant effect was modest and the study had limitations.
How this was made
The 30-second read
Why it matters
The data provide early evidence of safety and efficacy, positioning Lilly as a potential player in psychedelic depression treatments, though further trials are required.
Market read
New clinical data may influence biotech valuations, especially firms developing psychedelic therapies, but immediate price moves are likely modest.
What to watch
Regulatory hurdles for Schedule 1 substances and the need for larger Phase 3 trials could delay any material benefit to Lilly.
Background
The article reports the first public release of Phase 2b trial results for mebufotenin (5‑MeO‑DMT) nasal spray, funded by AtaiBeckley, a subsidiary of Eli Lilly.
Ticker impact
Eli Lilly's subsidiary AtaiBeckley funded the Phase 2b trial of mebufotenin, making Lilly indirectly linked to the new clinical data.
potential modest upside as investors reassess Lilly's biotech exposure
Trial shows safety and efficacy signals, yet the drug is still years from market; impact depends on further development.
Market effects
Adds credibility to the emerging psychedelic therapeutics sector, may spur interest in other biotech firms pursuing similar pathways.
Limited to U.S. biotech investors; no broad regional effect.
Highlights growing global research into psychedelic medicines, but immediate market impact is confined to biotech equities.
Counterpoint
Skeptics note the modest response rates and exclusion of patients with prior ketamine or ECT, suggesting limited commercial upside.
Key entities
- CompanyEli Lilly and Company
Parent of AtaiBeckley, a biotech sponsor of the trial.
- CompanyAtaiBeckley
Biotech subsidiary of Eli Lilly funding the mebufotenin trial.
